source
- Merck briefly lists, then removes, phase 2 trial of PD-1xVEGF bispecific with TROP2 ADCMerck & Co. posted a clinical trial listing for a phase‑2 study combining its PD‑1xVEGF bispecific antibody (MK‑2010) with the TROP2‑directed antibody‑drug conjugate sac‑TMT. The listing, shown as…
- 529 Commerce recalls Rooted in Rare Aquafaba Powder over possible undeclared egg allergen529 Commerce, LLC of Parkland, Florida announced a recall of its Rooted in Rare brand Aquafaba Powder. The recall includes 3,860 units packaged in 4‑oz and 12‑oz flexible foil pouches that were so…